Table 3.

Characteristics of the responders following decitabine therapy

BM blast %
Patient no.Age, y/sexDiagnosisSalvage no.BeforeAfterKaryotypeDose, mg/m2 × daysResponseResponse duration, wkSurvival, wk
6 65/M AML 1 41 0 -5/-7 5 × 10 CR 7 18
11 31/M AML 2 16 3 t(3;3) 10 × 10 CR 21 62
20 55/F AML 1 11 0 Diploid 15 × 10 HI 4 29
41 77/M AML 1 35 2 Diploid 15 × 10 HI 4 43
44 78/M AML 2 8 2 Diploid 15 × 10 HI 2 44
16 65/M AML 1 60 3 -7 15 × 10 CR 17 35
19 48/F AML 3 72 4 Diploid 15 × 10 CR 7 47
50 27/F AML 4 5 0 Diploid 15 × 10 CR 59+ 60+
48 21/F MDS 0 13 1 Diploid 15 × 10 HI 13 16
17 72/M MDS 1 9 1 -5/-7 15 × 10 CR 29 50
33 83/M MDS 0 20 2 5q-, +8 15 × 15 CR 48 61+
22 64/M MDS 1 10 1 +8 (100) 20 × 10 HI 1 44
7 43/M CML 1 18 2 Ph (100) 5 × 10 PHR 8 111+
18 69/M CML 1 1 0 Ph 15 × 10 CHR 9 19
43 45/F CML 2 30 6 Ph+ other 15 × 10 2nd CP 1 20
46 55/M CML 3 27 3 Ph+ other 15 × 10 CHR 8 28